Cubist Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cubist Pharmaceuticals, Inc.
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
Swiss biotech Numab Therapeutics has raised an oversubscribed series C financing of CHF100m to accelerate the development of its multispecific antibodies, from investors attracted by the company’s thoughtful approach to developing its technology.
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
A 2008 law that limited exclusivity for certain antibiotics to three years does not apply to Allergan’s Avycaz, which combines an approved old antibiotic active moiety and a new active moiety, CDER exclusivity board concludes.
- Other Names / Subsidiaries
- Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.